Skip to content

Study to assess the effectiveness of Malayuphal Modak in heavy menstrual bleeding during puberty.

A RANDOMIZED OPEN CONTROLLED CLINICAL TRIAL TO ASSESS THE ADD ON EFFECT OF MALAYUPHALA MODAK IN TARUNI ASRUGDAR W.S.R. TO PUBERTY MENORRHAGIA - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103507
Enrollment
92
Registered
2026-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N922- Excessive menstruation at puberty

Interventions

None listed

Sponsors

Dr Vaishnavi Dnyaneshwar Ghawat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with prolonged cycle more than 7 days & excessive bleeding per vagina i.e 3-5 large sized Stayfree secure pads in 24 hours during menstruation. 2) Onset of menarche not exceeding more than 2 years at the time of registration. 3) Polymenorrhagia. 4) Inter-menstrual bleeding (Anruta artava- Chakradatta). 5) Patients with Hb-9 to 11 gm/dl. 6) Patients with BMI between 18-28 . 7) Age-10 to 16 years unmarried girls irrespective of caste, socio-economic status.

Exclusion criteria

Exclusion criteria: 1. Physical examination suggestive of Hirsuitism, Acanthosis Nigricans. 2. BMI more than 30. 3. K/C/O Endocrinal Disorder like Hypo or Hyperthyroidism, PCOS . 4. K/C/O Bleeding Dyscrasias. 5. K/C/O Pelvic organ pathology. 6.K/C/O systemic disorders.

Design outcomes

Primary

MeasureTime frame
To evaluate the Add on effect of MALAYUPHALA MODAK along with Reassurance ferric Ascorbate in the management of Taruni Asrugdar W.S.R. to Puberty Menorrhagia.Timepoint: To evaluate the Add on effect of MALAYUPHALA MODAK along with Reassurance ferric Ascorbate in the management of Taruni Asrugdar W.S.R. to Puberty Menorrhagia.

Secondary

MeasureTime frame
1)To reduce amount of bleeding due to Menorrhagia 2)To assess improvement by parameters like PBAC. 3)To reduce the duration of menstural cycle due to Menorrhagia. 4)To study th etio-pathology of Asrugdar & puberty menorrhagia in detail. 5)To assess the improvement in other assessment parameter(with or without clots,Angamarda etc) 6)To achieve the outcome of study in 90 days ( 3 Menstrual cycles) by assessment of the condition in each cycle. 7)To assure post treatment cycles are symptom free.Timepoint: 1)To reduce amount of bleeding due to Menorrhagia. 2)To assess improvement by parameters like PBAC. 3)To reduce the duration of menstural cycle due to Menorrhagia. 4)To study th etio-pathology of Asrugdar & puberty menorrhagia in detail. 5)To assess the improvement in other assessment parameter(with or without clots,Angamarda etc) 6)To achieve the outcome of study in 90 days ( 3 Menstrual cycles) by assessment of the condition in each cycle. 7)To assure post treatment cycles are symptom free.

Countries

India

Contacts

Public ContactDr Vaishnavi Dnyaneshwar Ghawat

Yashwant Ayurvedic College postgraduate Training and Research centre Kodoli kolhapur

vishalaturlapati@gmail.com9960217429

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026